Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**aripiprazole + lamotrigine** refers to the concomitant use of the two drugs: **aripiprazole**, an atypical antipsychotic, and **lamotrigine**, a mood stabilizer and anticonvulsant. - **Aripiprazole** acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors, leading to modulation of dopaminergic and serotonergic neurotransmission. - **Lamotrigine** inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and suppressing the release of excitatory neurotransmitters like glutamate and aspartate. The combination is sometimes used in the management of **bipolar disorder**, particularly for the long-term prevention of mood episode relapses, and may be considered for major depressive disorder as augmentation in select cases. Clinical studies report efficacy in prolonging time to relapse in bipolar I disorder, though significance over monotherapy is variable[2][4][5]. Adverse effects reported include the potential for additive CNS depression, rare cases of intention tremor, and possibly an increased risk for neuroleptic malignant syndrome (NMS) when used with other antipsychotics or in vulnerable patients[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aripiprazole + lamotrigine.